MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Funding Strategies for Architects (Private Equity, Venture & Risk Capital)
Intermediaries: Risk Capital (Angel, Seed, Venture Capital, SPAC, Strategic Corporate, Private Equity, Banking)
Intermediaries: Banking Companies
Intermediaries: Private Equity, Investment Banking & Financial Analysis and Services Companies
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Geron Corporation (NASDAQ: GERN)*
Organization & Developments: Geron
Parents
Geron Corporation (NASDAQ: GERN)*
Children
*Discovery of mechanisms and therapeutics that impact the aging process
*Organization & Developments: Geron (Archives 2010 - 2016)
*Organization & Developments: Geron (Archives 2017)
*Organization & Developments: Geron (Archives 2018-2020)
2021: Geron: Even The Dead Can Be Useful
2022: Geron - Low-Priced Giant_ seekingalpha.com
2022: Geron (GERN) Investor Presentation - Slideshow_seekingalpha.com
2022: Geron Announces Positive Phase III Data, Likely to Seek FDA Approval in MDS
2022: Geron: A Major Catalyst For Shareholders Arrives In January - At Last_seekingalpha.com
2022: Geron: Expect Topline MDS Data In Early January_ seekingalpha.com
2022: Geron: The First Success Story Of The New Year_ seekingalpha.com
2023: Data to dollars: Geron sells stock to raise over $200M after PhIII readout on MDS drug
2023: Geron blood cancer therapy granted FDA standard review
2023: Geron blood cancer therapy under EU review (NASDAQ:GERN)
2023: Geron Corporation 2023 Q3 - Results - Earnings Call Presentation
2023: Geron Corporation Stock: Another Buying Opportunity (NASDAQ:GERN)
2023: Geron Corporation: The FDA, Catalysts And New Competition From Old Drugs
2023: Geron lines up commercial leadership for imetelstat launch_ seekingalpha.com
2023: Geron reports positive late-stage data on imetelstat in MDS
2023: Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case_ seekingalpha.com
2023: Geron: Where Things Stand With Several Milestones On The Horizon_ seekingalpha.com
2023: Geron's Data Allows Development Of Several Catalysts_seekingalpha.com
2023: Geron's Imetelstat Could Find Its Place In MDS Treatment, Yet Prudence Is Advised_ seekingalpha.com
2023: Ready To Face The Competition With Imetelstat In Lower-Risk MDS (GERN)
2024: After 33 years, Geron’s first approval marks a turn in Nobel-winning science
2024: Considering The Merits Of A Gamble On Geron Corporation
2024: Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with T
2024: Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
2024: Geron Corporation 2024 Q2 - Results - Earnings Call Presentation
2024: Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
2024: Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
2024: Geron: A Post Earnings And Funding Announcement Assessment
2024: Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
2024: Geron: Derisked And Highly Attractive After Approval
2024: Geron: Innovative Rytelo Enters A Challenging MDS Market
2024: Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)_seekingalpha.com
2024: US FDA staff flags concerns about Geron's anemia treatment
2025: Conservative Vision Of A Positive Future For Geron
2025: Favourable Signals For Geron: Numerous Insiders Acquired Stock
2025: GERN) plans one-third cut as 2026 operating expenses expected below 2025
2025: Geron Corp: How Concerned Should We Be About Rytelo Sales?_ seekingalpha.com
2025: Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential
2025: Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
2025: Geron Corporation's (NASDAQ:GERN) Shares Climb 30% But Its Business Is Yet to Catch Up
2025: Geron stock plunges 30% amid Rytelo sales concerns (update)
2025: Geron stock plunges 30% amid Rytelo sales concerns (update)
2025: Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)
2025: Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales
2025: Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)
2025: Is Geron A Buyout Target? The RPRX Deal Says No
Jumps
*Key People: Geron
Finance & Acquisitions: Geron